IBA Reports Full Year 2020 Results

RESILIENT PERFORMANCE ACROSS BUSINESS LINES

GOOD ORDER INTAKE AND RECORD BACKLOG

POSITIVE REBIT AND BOTTOM LINE

STRONG BALANCE SHEET WITH EUR 65 MILLION NET CASH AT YEAR END

Louvain-la-Neuve, Belgium, 25 March 2021 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated annual results for the 2020 financial year.

	YE 2020 (EUR 000)	YE 2019 (EUR 000)	Variance (EUR 000)	Variance %
Net Sales	311 955	282 552	29 403	+10.4%
Proton Therapy	189 150	158 273	30 877	+19.5%
Dosimetry	51 060	53 846	-2 786	-5.2%
Other Accelerators	71 745	70 433	1 312	+1.9%
REBITDA	55 985	12 459	43 526	+349%
% of Sales	17.9%	+4.4%
REBIT	40 406	87	40 319	46 344%
% of Sales	13.0%	0.0%
Profit Before Tax	33 054	10 766	22 288	+207%
% of Sales	10.6%	+3.8%
NET RESULT	31 921	7 610	24 311	319%
% of Sales	10.2%	+2.7%